WebDoctor Encyclopedia

Central nervous system Lymphomas

Primary vitreoretinal lymphoma

Primary vitreoretinal lymphoma is a rare lymphoma that starts in the gel and retina of the eye and often mimics uveitis. It is diagnosed by vitreous biopsy and treated with eye injections, radiotherapy or chemotherapy.

Medically reviewed Last reviewed October 21, 2026

What is primary vitreoretinal lymphoma?

Primary vitreoretinal lymphoma (PVRL) is a rare cancer of the immune system that starts inside the eye. It affects the vitreous, the clear jelly that fills the eyeball, and the retina, the light-sensitive layer at the back of the eye. In most cases it is a type of diffuse large B-cell lymphoma, a fast-growing lymphoma made of abnormal B lymphocytes.

PVRL is considered a form of primary central nervous system lymphoma, because the retina is an extension of the brain. The word “primary” means that, at diagnosis, the lymphoma is found in the eye but not yet in the brain (Soussain et al., 2021).

The main challenge with PVRL is that it can look like inflammation inside the eye (uveitis). People may be treated for uveitis for months before the true cause is found. The disease itself may seem slow at first, but it carries a high risk of later spread to the brain, which is the main threat to life.

How it differs from primary CNS lymphoma of the brain

PVRL belongs to the same family as lymphoma that starts in the brain, described on our page on primary central nervous system lymphoma. The two often occur in the same person, either together or one after the other.

Feature Primary CNS lymphoma of the brain Primary vitreoretinal lymphoma
First site Brain, spinal cord or brain fluid Vitreous and retina of the eye
First symptoms Headache, confusion, weakness, seizures Floaters and blurred vision
Common misdiagnosis Stroke or other brain tumour Uveitis
Diagnosis Brain biopsy Sample of the vitreous
Treatment High-dose methotrexate-based chemotherapy Eye treatment, often with systemic chemotherapy
Link Some patients also have eye disease Most patients later develop brain disease

1. Key facts at a glance

Feature Details
Type of cancer Lymphoma, usually diffuse large B-cell type, starting inside the eye
How common Rare; a small fraction of primary CNS lymphomas
Typical age Usually over 50; median in the 60s
Eyes affected Often both eyes, sometimes one after the other
Usual first sign Floaters and blurred vision without pain or redness
Main diagnostic test Vitreous biopsy (vitrectomy)
Main treatments Injections of methotrexate or rituximab into the eye, eye radiotherapy, high-dose methotrexate
Main risk Spread to the brain
Outlook Vision can often be saved; survival depends mainly on brain involvement

2. Types

Lymphoma inside the eye

Type Description
Primary vitreoretinal lymphoma Starts in the vitreous and retina; the subject of this article
Vitreoretinal lymphoma with brain involvement The eye and brain are affected at the same time
Secondary vitreoretinal lymphoma Lymphoma from the brain or elsewhere in the body spreads to the eye
Uveal (choroidal) lymphoma A different disease, usually a slow-growing marginal zone lymphoma in the layer under the retina

By cell type

Cell type Notes
Diffuse large B-cell lymphoma The vast majority
T-cell lymphoma Rare

3. Causes and risk factors

The cause is not known. Experts think that the lymphoma cells may change outside the eye and then settle and grow in the eye and brain, where the immune system is less active (Soussain et al., 2021).

Factor Notes
Age Mostly older adults
Weakened immune system Such as HIV or organ transplant medicines; raises the risk of CNS lymphoma
Gene changes in the lymphoma MYD88 L265P and CD79B changes are common
Infections EBV is linked mainly to lymphoma in people with weak immunity
Inherited factors No inherited cause known

4. How does it look

On eye examination

Finding Description
Vitreous cells Haze or clumps and sheets of cells in the eye jelly
Retinal lesions Creamy-white or yellow spots under the retina
“Leopard-skin” pattern Patchy dark and light spots on the retina
Little inflammation Usually no pain, redness or fluid swelling at the centre of the retina
Both eyes Often affected, though not always to the same degree

An international consensus noted that a heavy build-up of cells in the vitreous without swelling of the central retina is a typical pattern (Carbonell et al., 2021).

Eye imaging

Test Typical findings
Optical coherence tomography (OCT) Bright deposits and bumps under the retina
Fundus autofluorescence Patchy changes in the pigment layer
Fluorescein angiography Spots of abnormal staining in a granular pattern

Under the microscope

Feature Description
Lymphoma cells Large cells with irregular nuclei and little cytoplasm
Fragility The cells break down easily, so samples must be processed quickly
Background Many reactive T cells and debris

5. Symptoms

Common symptoms

  • Floaters: dark spots or threads that drift across vision
  • Blurred or cloudy vision
  • Symptoms usually come on gradually and are painless
  • The eye is often not red

Less common symptoms

Symptom Possible cause
Loss of central vision Lymphoma under the retina near the macula
Sensitivity to light Mild inflammation
Symptoms in the second eye Spread to the other eye
Headache, confusion, personality change Spread to the brain
Weakness, unsteadiness or seizures Spread to the brain

When to seek medical advice

See an eye doctor for new floaters or blurred vision, especially if you are over 50. If you have been treated for uveitis that keeps returning or does not improve with steroids, ask whether lymphoma has been ruled out.

6. Diagnosis

Diagnosis needs close teamwork between eye specialists, pathologists and haematologists.

Step What is done
Detailed eye examination Looks for typical vitreous and retinal signs
Eye imaging OCT, autofluorescence and angiography
Stop steroids Steroids should usually be stopped at least two weeks before sampling
Diagnostic vitrectomy Surgery to remove vitreous for testing
Cytology and flow cytometry Look for lymphoma cells and show whether they come from one clone
Interleukin levels Ratio of IL-10 to IL-6 in eye fluid
Molecular tests MYD88 mutation and immunoglobulin gene rearrangement
Retinal biopsy Rarely, if other tests are inconclusive

Steroids can kill lymphoma cells and make the biopsy negative, which is why they are stopped beforehand (Carbonell et al., 2021).

How accurate are the tests?

A systematic review compared the sensitivity of different tests (Huang et al., 2024).

Test Approximate share of PVRL cases detected
IL-10 to IL-6 ratio above 1 About 89%
Flow cytometry of vitreous About 88%
Immunoglobulin gene rearrangement About 85%
MYD88 L265P mutation About 70%
CD79B mutation About 35%

Because no single test is perfect, doctors usually combine several.

Why diagnosis takes time

Lymphoma cells in the vitreous are few and fragile. Samples must reach the laboratory quickly, and even then the cells may not be recognisable. Steroid drops or tablets given for suspected uveitis can temporarily improve the eye and shrink the lymphoma, which delays the diagnosis further.

Some people need more than one vitrectomy before the diagnosis is confirmed. Your team may combine several laboratory tests on the same sample to make the most of it.

Staging tests

Test Purpose
MRI of the brain Looks for brain involvement
Lumbar puncture Checks the brain and spinal fluid for lymphoma cells
CT or PET-CT of the body Rules out lymphoma elsewhere
HIV test and blood tests Assess immunity and fitness for treatment

7. Treatment

There is no single standard treatment. Plans are based on small studies and expert experience, and should be made by a team that includes an eye specialist and a haematologist or neuro-oncologist.

Treatments for the eye

Treatment Details
Methotrexate injections into the eye Given repeatedly over months until the lymphoma clears
Rituximab injections into the eye An antibody against B cells; an alternative or addition
Eye radiotherapy Low-dose radiotherapy to both eyes

These local treatments usually clear the lymphoma from the eye well, but they do not stop it from appearing later in the brain (Soussain et al., 2021).

Treatments for the whole body

Treatment Details
High-dose methotrexate Intravenous chemotherapy that reaches the brain and eye
Combination chemotherapy Methotrexate with other drugs, as for primary CNS lymphoma
Intensive chemotherapy with stem cell transplant Mostly for relapse in fit patients

A Japanese study of 54 patients found that those who completed high-dose methotrexate after eye injections had a lower risk of brain spread (Motomura et al., 2024).

Treatment of relapse

Option Notes
Repeat eye injections or radiotherapy For relapse in the eye
Ibrutinib Tablet that blocks a B-cell signalling pathway
Lenalidomide Tablet that modulates the immune system
Temozolomide Oral chemotherapy
High-dose chemotherapy and stem cell transplant For brain relapse in fit patients

Side effects

Treatment Possible side effects
Eye injections Irritation of the cornea, raised eye pressure, small risk of infection
Eye radiotherapy Dry eye, cataract, rarely retinal damage
High-dose methotrexate Kidney strain, mouth sores, low blood counts; requires hospital stay and monitoring
Ibrutinib Bleeding risk, heart rhythm problems
Vitrectomy Cataract, raised eye pressure, rarely retinal detachment

8. Outlook (prognosis)

Vision can often be protected or improved with treatment. The main factor for survival is whether the lymphoma spreads to the brain.

Finding Details
Risk of brain spread High; about 78% within five years in one Japanese series
Five-year survival About 69% in the same series
Factors raising brain risk Disease in both eyes and a clonal B-cell population on flow cytometry
Factor lowering brain risk Completing systemic high-dose methotrexate

These figures come from Motomura et al. (2024). Results vary between centres and treatment strategies.

9. Follow-up

Check Typical timing
Eye examination and OCT Every 1-3 months at first
Brain MRI Every 3-6 months for the first years
Neurological review At each visit
Blood tests During and after chemotherapy

Report any new floaters, vision changes, headaches, confusion or weakness straight away.

10. Living with primary vitreoretinal lymphoma

  • Keep all eye and brain scan appointments
  • Use eye drops as prescribed after injections or surgery
  • Do not drive if your vision does not meet legal standards; ask your eye doctor
  • Ask about low-vision aids if your sight is affected
  • Tell family about symptoms of brain involvement to watch for
  • Seek support from lymphoma and sight-loss charities

Coping with vision changes

Losing some sight can affect reading, driving, work and confidence. Eye clinics can refer you to low-vision services, which offer magnifiers, lighting advice and training. Sight-loss charities provide practical tips, emotional support and help with benefits. It is normal to feel anxious about the risk of brain involvement, and talking with your specialist nurse or a counsellor can help.

11. Frequently asked questions

Question Answer
Is it an eye cancer or a blood cancer? It is a lymphoma, a cancer of immune cells, that starts inside the eye
Why was I first told I had uveitis? The two conditions look very similar, and lymphoma often hides behind inflammation
Will I go blind? Most people keep useful vision with treatment
Will it spread to my brain? The risk is high, which is why brain scans and sometimes systemic chemotherapy are recommended
Are the eye injections painful? The eye is numbed first; most people feel pressure rather than pain
Should I stop my steroid eye drops? Only on your doctor’s advice; they may be paused before a biopsy
Can it be cured? Some patients stay in long-term remission, especially if the brain is never affected

12. Questions to ask your care team

  • Which tests confirmed the diagnosis?
  • Is the lymphoma in one eye or both?
  • Has my brain and spinal fluid been checked?
  • Do you recommend eye treatment alone or systemic chemotherapy as well?
  • How many eye injections will I need?
  • What are the signs of brain spread that I should watch for?
  • Who should I call if I notice new symptoms between visits?
  • Are there clinical trials I could join?

Resources

  1. Carbonell, D. et al. (2021) ‘Consensus recommendations for the diagnosis of vitreoretinal lymphoma’, Ocular Immunology and Inflammation, 29(3), pp. 507-520.
  2. Huang, R.S. et al. (2024) ‘Diagnostic methods for primary vitreoretinal lymphoma: a systematic review’, Survey of Ophthalmology, 69(3), pp. 456-464.
  3. Motomura, Y. et al. (2024) ‘Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma’, British Journal of Haematology, 204(4), pp. 1279-1287.
  4. Soussain, C., Malaise, D. and Cassoux, N. (2021) ‘Primary vitreoretinal lymphoma: a diagnostic and management challenge’, Blood, 138(17), pp. 1519-1534.
  5. National Cancer Institute (2026) Primary CNS Lymphoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/lymphoma/hp/primary-cns-lymphoma-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.